MediciNova
MediciNova is a biopharmaceutical company focused on acquiring and developing small-molecule therapeutics for diseases with unmet medical needs, with emphasis on the United States market. Its diverse pipeline includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for neurological disorders; MN-221 (bedoradrine) for acute asthma exacerbations; MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin-binding agent for solid tumors. The company pursues collaborations and alliances to advance its portfolio, including vaccine development efforts with BioComo and Mie University and partnerships with Japanese pharmaceutical companies. Development efforts focus on neurology, fibrosis, and oncology, aiming to address medical needs through clinical and preclinical programs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.